{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T14:40:08Z","timestamp":1778251208870,"version":"3.51.4"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2015,4,14]],"date-time":"2015-04-14T00:00:00Z","timestamp":1428969600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2015,8]]},"DOI":"10.1007\/s00277-015-2359-2","type":"journal-article","created":{"date-parts":[[2015,4,12]],"date-time":"2015-04-12T23:40:02Z","timestamp":1428882002000},"page":"1381-1388","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":82,"title":["CD38 expression predicts poor prognosis and might be a potential therapy target in extranodal NK\/T cell lymphoma, nasal type"],"prefix":"10.1007","volume":"94","author":[{"given":"Liang","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hua","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peng-fei","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yue","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhong-jun","family":"Xia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui-qiang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-jing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,4,14]]},"reference":[{"key":"2359_CR1","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","volume":"26","author":"J Vose","year":"2008","unstructured":"Vose J, Armitage J, Weisenburger D, International TCLP (2008) International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol 26:4124\u20134130","journal-title":"J Clin Oncol"},{"key":"2359_CR2","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1007\/s12185-012-1174-y","volume":"96","author":"L Wang","year":"2012","unstructured":"Wang L, Xia ZJ, Huang HQ, Lu Y, Zhang YJ (2012) Cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) in the treatment of stage IE\/IIE extranodal natural killer\/T cell lymphoma, nasal type: 13-year follow-up in 135 patients. Int J Hematol 96:617\u2013623","journal-title":"Int J Hematol"},{"key":"2359_CR3","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1016\/j.ijrobp.2003.12.006","volume":"59","author":"WS Koom","year":"2004","unstructured":"Koom WS, Chung EJ, Yang WI et al (2004) Angiocentric T-cell and NK\/T-cell lymphomas: radiotherapeutic viewpoints. Int J Radiat Oncol Biol Phys 59:1127\u20131137","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2359_CR4","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1002\/cncr.11908","volume":"100","author":"CC Li","year":"2004","unstructured":"Li CC, Tien HF, Tang JL et al (2004) Treatment outcome and pattern of failure in 77 patients with sinonasal natural killer\/T-cell or T-cell lymphoma. Cancer 100:366\u2013375","journal-title":"Cancer"},{"key":"2359_CR5","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.oraloncology.2006.11.020","volume":"44","author":"Y Guo","year":"2008","unstructured":"Guo Y, Lu JJ, Ma X et al (2008) Combined chemoradiation for the management of nasal natural killer (NK)\/T-cell lymphoma: elucidating the significance of systemic chemotherapy. Oral Oncol 44:23\u201330","journal-title":"Oral Oncol"},{"key":"2359_CR6","doi-asserted-by":"crossref","first-page":"4410","DOI":"10.1200\/JCO.2011.35.6287","volume":"29","author":"M Yamaguchi","year":"2011","unstructured":"Yamaguchi M, Kwong YL, Kim WS et al (2011) Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)\/T-cell lymphoma, nasal type: the NK-Cell Tumor Study Group study. J Clin Oncol 29:4410\u20134416","journal-title":"J Clin Oncol"},{"key":"2359_CR7","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1002\/ajh.21256","volume":"83","author":"B Wang","year":"2008","unstructured":"Wang B, Li XQ, Ma X, Hong X, Lu H, Guo Y (2008) Immunohistochemical expression and clinical significance of P-glycoprotein in previously untreated extranodal NK\/T-cell lymphoma, nasal type. Am J Hematol 83:795\u2013799","journal-title":"Am J Hematol"},{"key":"2359_CR8","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1111\/j.1365-2141.2005.05694.x","volume":"130","author":"M Ando","year":"2005","unstructured":"Ando M, Sugimoto K, Kitoh T et al (2005) Selective apoptosis of natural killer-cell tumours by l-asparaginase. Br J Haematol 130:860\u2013868","journal-title":"Br J Haematol"},{"key":"2359_CR9","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1002\/cncr.27752","volume":"119","author":"L Wang","year":"2013","unstructured":"Wang L, Wang ZH, Chen XQ et al (2013) First-line combination of gemcitabine, oxaliplatin, and L-asparaginase (GELOX) followed by involved-field radiation therapy for patients with stage IE\/IIE extranodal natural killer\/T-cell lymphoma. Cancer 119:348\u2013355","journal-title":"Cancer"},{"key":"2359_CR10","doi-asserted-by":"crossref","first-page":"3294","DOI":"10.1002\/cncr.26629","volume":"118","author":"M Jiang","year":"2012","unstructured":"Jiang M, Zhang H, Jiang Y et al (2012) Phase 2 trial of \u201csandwich\u201d l-asparaginase, vincristine, and prednisone chemotherapy with radiotherapy in newly diagnosed, stage IE to IIE, nasal type, extranodal natural killer\/T-cell lymphoma. Cancer 118:3294\u20133301","journal-title":"Cancer"},{"key":"2359_CR11","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/0167-5699(94)90148-1","volume":"15","author":"F Malavasi","year":"1994","unstructured":"Malavasi F, Funaro A, Roggero S, Horenstein A, Calosso L, Mehta K (1994) Human CD38: a glycoprotein in search of a function. Immunol Today 15:95\u201397","journal-title":"Immunol Today"},{"key":"2359_CR12","doi-asserted-by":"crossref","first-page":"328","DOI":"10.2119\/2006-00099.Lund","volume":"12","author":"FE Lund","year":"2006","unstructured":"Lund FE (2006) Signaling properties of CD38 in the mouse immune system: enzyme-dependent and -independent roles in immunity. Mol Med 12:328\u2013333","journal-title":"Mol Med"},{"key":"2359_CR13","doi-asserted-by":"crossref","first-page":"342","DOI":"10.2119\/2006-00110.Morabito","volume":"12","author":"F Morabito","year":"2006","unstructured":"Morabito F, Damle RN, Deaglio S, Keating M, Ferrarini M, Chiorazzi N (2006) The CD38 ectoenzyme family: advances in basic science and clinical practice. Mol Med 12:342\u2013344","journal-title":"Mol Med"},{"key":"2359_CR14","doi-asserted-by":"crossref","first-page":"5173","DOI":"10.1182\/blood-2007-08-108605","volume":"111","author":"PE Patten","year":"2008","unstructured":"Patten PE, Buggins AG, Richards J et al (2008) CD38 expression in chronic lymphocytic leukemia is regulated by the tumor microenvironment. Blood 111:5173\u20135181","journal-title":"Blood"},{"key":"2359_CR15","first-page":"1095","volume":"7","author":"Y Khagi","year":"2014","unstructured":"Khagi Y, Mark TM (2014) Potential role of daratumumab in the treatment of multiple myeloma. Onco Targets Ther 7:1095\u20131100","journal-title":"Onco Targets Ther"},{"key":"2359_CR16","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.5604\/17322693.1129819","volume":"68","author":"A Jurczyszyn","year":"2014","unstructured":"Jurczyszyn A, Kosmaczewska A, Skotnicki AB (2014) Daratumumab\u2014breakthrough drug in multiple myeloma therapy. Postepy Hig Med Dosw (Online) 68:1352\u20131360","journal-title":"Postepy Hig Med Dosw (Online)"},{"key":"2359_CR17","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1586\/14737140.2013.829641","volume":"13","author":"J Kuroda","year":"2013","unstructured":"Kuroda J, Nagoshi H, Shimura Y, Taniwaki M (2013) Elotuzumab and daratumumab: emerging new monoclonal antibodies for multiple myeloma. Expert Rev Anticancer Ther 13:1081\u20131088","journal-title":"Expert Rev Anticancer Ther"},{"key":"2359_CR18","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S0037-1963(03)00132-X","volume":"40","author":"ES Jaffe","year":"2003","unstructured":"Jaffe ES, Krenacs L, Raffeld M (2003) Classification of cytotoxic T-cell and natural killer cell lymphomas. Semin Hematol 40:175\u2013184","journal-title":"Semin Hematol"},{"key":"2359_CR19","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/1756-8722-6-44","volume":"6","author":"N Lin","year":"2013","unstructured":"Lin N, Song Y, Zheng W et al (2013) A prospective phase II study of L-asparaginase- CHOP plus radiation in newly diagnosed extranodal NK\/T-cell lymphoma, nasal type. J Hematol Oncol 6:44","journal-title":"J Hematol Oncol"},{"key":"2359_CR20","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.3109\/10428194.2011.561388","volume":"52","author":"H Huang","year":"2011","unstructured":"Huang H, Lin Z, Lin X, Cai Q, Xia Z, Jiang W (2011) Long-term outcomes of patients with newly diagnosed extranodal natural killer\/T-cell lymphoma treated by etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin regimen: a single-institution experience. Leuk Lymphoma 52:1041\u20131048","journal-title":"Leuk Lymphoma"},{"key":"2359_CR21","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1007\/s12032-014-0860-4","volume":"31","author":"L Wang","year":"2014","unstructured":"Wang L, Wang WD, Xia ZJ, Zhang YJ, Xiang J, Lu Y (2014) Combination of gemcitabine, l-asparaginase, and oxaliplatin (GELOX) is superior to EPOCH or CHOP in the treatment of patients with stage IE\/IIE extranodal natural killer\/T cell lymphoma: a retrospective study in a cohort of 227 patients with long-term follow-up. Med Oncol 31:860","journal-title":"Med Oncol"},{"key":"2359_CR22","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","volume":"17","author":"BD Cheson","year":"1999","unstructured":"Cheson BD, Horning SJ, Coiffier B et al (1999) Report of an international workshop to standardize response criteria for non-Hodgkin\u2019s lymphomas. NCI Sponsored International Working Group. J Clin Oncol 17:1244","journal-title":"J Clin Oncol"},{"key":"2359_CR23","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.4049\/jimmunol.1003032","volume":"186","author":"M Weers de","year":"2011","unstructured":"de Weers M, Tai YT, van der Veer MS et al (2011) Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J Immunol 186:1840\u20131848","journal-title":"J Immunol"},{"key":"2359_CR24","doi-asserted-by":"crossref","first-page":"3864","DOI":"10.1182\/blood.V94.11.3864","volume":"94","author":"G Sconocchia","year":"1999","unstructured":"Sconocchia G, Titus JA, Mazzoni A et al (1999) CD38 triggers cytotoxic responses in activated human natural killer cells. Blood 94:3864\u20133871","journal-title":"Blood"},{"key":"2359_CR25","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1007\/s12032-013-0723-4","volume":"30","author":"L Wang","year":"2013","unstructured":"Wang L, Liao DZ, Zhang J, Xia ZJ, Peng XW, Lu Y (2013) Clinical significance of serum soluble interleukin-2 receptor-alpha in extranodal natural killer\/T-cell lymphoma (ENKTL): a predictive biomarker for treatment efficacy and valuable prognostic factor. Med Oncol 30:723","journal-title":"Med Oncol"},{"key":"2359_CR26","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1200\/JCO.2005.04.1384","volume":"24","author":"J Lee","year":"2006","unstructured":"Lee J, Suh C, Park YH et al (2006) Extranodal natural killer T-cell lymphoma, nasal-type: a prognostic model from a retrospective multicenter study. J Clin Oncol 24:612\u2013618","journal-title":"J Clin Oncol"},{"key":"2359_CR27","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1007\/s13277-013-1284-z","volume":"35","author":"L Wang","year":"2014","unstructured":"Wang L, Chi PD, Chen H, Xiang J, Xia ZJ, Zhang YJ (2014) Low level of high-density lipoprotein cholesterol correlates with poor prognosis in extranodal natural killer\/T cell lymphoma. Tumour Biol 35:2141\u20132149","journal-title":"Tumour Biol"},{"key":"2359_CR28","doi-asserted-by":"crossref","unstructured":"Wang L, Wu-Xiao ZJ, Chen XQ, Zhang YJ, Lu Y, Xia ZJ (2014) Hepatitis B virus infection correlates with poor prognosis of extranodal natural killer\/T cell lymphoma. Leuk Lymphoma 1\u20136. doi: 10.3109\/10428194.2014.953146","DOI":"10.3109\/10428194.2014.953146"},{"key":"2359_CR29","doi-asserted-by":"crossref","first-page":"309","DOI":"10.2119\/2007-00006.Czura","volume":"12","author":"AW Czura","year":"2006","unstructured":"Czura AW, Czura CJ (2006) CD38 and CD157: biological observations to clinical therapeutic targets. Mol Med 12:309\u2013311","journal-title":"Mol Med"},{"key":"2359_CR30","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1186\/1471-2407-14-890","volume":"14","author":"P Li","year":"2014","unstructured":"Li P, Jiang L, Zhang X, Liu J, Wang H (2014) CD30 expression is a novel prognostic indicator in extranodal natural killer\/T-cell lymphoma, nasal type. BMC Cancer 14:890","journal-title":"BMC Cancer"},{"key":"2359_CR31","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/s13277-011-0171-8","volume":"32","author":"L Wang","year":"2011","unstructured":"Wang L, Lin GN, Jiang XL, Lu Y (2011) Expression of ezrin correlates with poor prognosis of nasopharyngeal carcinoma. Tumour Biol 32:707\u2013712","journal-title":"Tumour Biol"},{"key":"2359_CR32","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1200\/JCO.2009.26.7609","volume":"28","author":"JR Brahmer","year":"2010","unstructured":"Brahmer JR, Drake CG, Wollner I et al (2010) Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 28:3167\u20133175","journal-title":"J Clin Oncol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-015-2359-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-015-2359-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-015-2359-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,31]],"date-time":"2020-08-31T20:13:58Z","timestamp":1598904838000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-015-2359-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4,14]]},"references-count":32,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2015,8]]}},"alternative-id":["2359"],"URL":"https:\/\/doi.org\/10.1007\/s00277-015-2359-2","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,4,14]]}}}